[Survival of probiotic microorganisms in the conditions in vitro imitating the process of human digestion].

PURPOSE OF THE STUDY: Assessment of survival bifidobacteria and lactobacteria under the conditions in vitro, simulating digestion in human stomach and intestine, and study of survival probiotic and indigenous microorganisms in co-cultivation on solid nutrient medium. MATERIALS AND METHODS: Probiotic microorganisms from commercial preparations Bifidobacterin and Lactobacterin, clinical isolates lactobacillus (Lactobacillus acidophilus No 1, L. brevis No 2) were used in experiments. Survival study of probiotic microorganisms was performed on a model in vitro, simulating the process of digestion in the human body. Assessment of the relationship of probiotic microorganisms and indigenous microorganisms was carried out in co-cultivation in vitro on solid nutrient medium. RESULTS: A significant reduction in the number of viable probiotic microorganisms during their incubation in model media was set as well as suppression of probiotic microorganisms growth by cultures of a clinical strains of lactobacillus, corresponding to biocompatibility by type "host against probiotic". CONCLUSION: While choosing probiotics in the treatment of dysbacterioses the character of relationship between probiotic microorganisms and indigenous microorganisms of a patient is recommended to be preliminarily tested. Also microorganisms of own microflora should be stimulated using modern prebiotics.

[Fructooligo- and fructopoly-saccharides in correction and prevention of intestinal microbiocenosis disorders in patients with bronchopulmonary pathology receiving antibacterial therapy].

AIM: To evaluate the clinical efficacy BUD "Stimbifid (LLC In-MIN"/LLC ("MedStar", Russia), which contains inulin, oligofructose, vitamins (C, B1, B6, B12, E, PP, folic acid, pantothenic acid, biotin) and minerals (zinc, selenium) in the correction and prevention of violations of the microbiota in patients with chronic and acute diseases of the lungs in the background and after antibiotic therapy (ABT). Was examined total of 50 patients with bronchopulmonary pathology on the background and after antibiotic therapy (including 30 people at a "Stimbifid" reception). The criteria for evaluating the effectiveness were: the dynamics of clinical symptoms, while in transit through the intestines of activated carbon ("carbolex test"), bacteriological examination of feces before and after treatment, the definition of short-chain fatty acids in the faeces before and after treatment. Based on the results of complex research was established the high efficiency of "Stimbifida" in the correction of microbiota in patients with chronic and acute diseases of the lungs in the background and after antibiotic therapy.

[Comparative assessment of survival of probiotic microorganisms from commercial preparations under the conditions in vitro].

PURPOSE OF THE STUDY: Assessment of survival of probiotic microorganisms from commercial preparations under the conditions in vitro simulates digestion in human stomach and intestine. MATERIALS AND METHODS: Probiotic microorganisms from domestic and foreign commercial preparations were used in experiments. Study of survival of probiotic microorganisms was carried out on the model in vitro simulates the conditions of digestion in the human body. RESULTS: A significant reduction in the number of viable probiotic microorganisms in the 20 of 23 studied commercial preparations during their incubation in the model media is established. Probiotic microorganisms in the preparations Bactisubtil, Sporobacterin and Biosporin possess a good survival under the conditions in vitro. CONCLUSION: The selection of probiotics for the correction of intestinal microbiocenosis requires an individual approach that takes into account the character of relations of probiotic microorganisms and indigenous microorganisms of patient as well as the possibility of using advanced prebiotics in the combine treatment of dysbacteriosis.

[Experimental study of sensitivity of probiotic microorganisms to antibacterial drugs].

PURPOSE OF THE STUDY: Investigation of sensitivity of probiotic microorganisms to antibacterial drugs. MATERIALS AND METHODS: Probiotic microorganisms from domestic and foreign commercial preparations were used in experiments. The study of sensitivity of probiotic microorganisms to antibacterial drugs was carried out using solid nutrient medium containing calculated amount of antibacterial drugs. RESULTS: Probiotic microorganisms are mainly sensitive to the representatives of the major classes of antibacterial drugs. Only some of the studied microorganisms are resistant to 1-4 antibiotics. CONCLUSION: When choosing a probiotic in the treatment of dysbacteriosis need to consider whether th antibiotic therapy was carried out. The use of antimicrobial drugs, even in therapeutic doses, reduces the viability of probiotic microorganisms and their survival in the gut.